187 related articles for article (PubMed ID: 31923731)
1. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
[No Abstract] [Full Text] [Related]
2. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
Taguchi S; Kawai T; Nakagawa T; Kume H
BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
[No Abstract] [Full Text] [Related]
3. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
[TBL] [Abstract][Full Text] [Related]
4. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
[TBL] [Abstract][Full Text] [Related]
5. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
8. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
Tsimafeyeu I; Tjulandin S
BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
[No Abstract] [Full Text] [Related]
9. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
[No Abstract] [Full Text] [Related]
10. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
12. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
13. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
[TBL] [Abstract][Full Text] [Related]
14. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
[No Abstract] [Full Text] [Related]
16. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
[TBL] [Abstract][Full Text] [Related]
17. Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
Asakawa K; Waratani M; Massey O; Holbrook T; Kondo M; Saito A; Nishiyama H
Int J Urol; 2024 Jul; 31(7):730-738. PubMed ID: 38468564
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
19. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
[TBL] [Abstract][Full Text] [Related]
20. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
Rexer H; Ohlmann CH; Retz M
Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
[No Abstract] [Full Text] [Related]
[Next] [New Search]